41 clinical trials
grid
list
download
Body (indexed field) | Identifiant (ID) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
22620 | any line, RECIST 1.1 | Ahmad Hussein Awada | Multiple | Boehringer Ingelheim | 1367.1 | Trial closed | An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit | ahmad.awada@hubruxelles.be | 1 | 1 | |
22685 | Unresecable or metastatic | Amelie Deleporte | Stomach - Duodenum-esogastric junction | Astellas | 8951-CL-0301 | Trial closed for recruitment | A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | amelie.deleporte@hubruxelles.be | 3 | 3 | |
22817 | c-Kit positive. Progression under imatinib | Thierry Gil | Stomach - Duodenum-esogastric junction | AB Science | AB11002 | Trial closed | AB11002 A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib to sunitinib in patients with gastrointestinla stromal tumor after progression with imatinib. | thierry.gil@hubruxelles.be | 3 | 3 | |
22632 | any line, RECIST 1.1 | Philippe Aftimos | Multiple | Amcure GmbH | AMC303-01 | Trial closed | A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin | philippe.aftimos@hubruxelles.be | 1/1b | 1 | |
22696 | KRAS/RAS mutation | Nuria Kotecki | Multiple | Pfizer | B9991033 | Trial closed | A phase 1b/2 study to evaluate safety and clinical activity of Avelumab in combination with Binimetinib with or without Talazoparib in patients with locally advanced or metastatic ras-mutant solid tumors | Nuria.Kotecki@hubruxelles.be | 1/2 | 1 | |
22715 | Stage IV unresecable ESCC. Measurable or evaluable disease (RECIST v1.1). ECOG Performance Status ? 1. Adequate organ function. Newly obtained or archival tissue sample available. | Amelie Deleporte | Esophagus | BeiGene | BGB-A317-306 | Trial closed for recruitment | A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination with Chemotherapy as First-Line Treatment in Patients with Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | amelie.deleporte@hubruxelles.be | 3 | 3 | |
28445 | unresectable liver metastases | Alain Hendlisz | Multiple | Highlight Therapeutics S.L. | BOT112-02 | Trial closed | Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophageal junction cancer | alain.hendlisz@hubruxelles.be | 2 | 2 | |
22758 | ECOG 0 or 1 | Ahmad Hussein Awada | Multiple | BMS - Bristol Myers Squibb int. | CA209358 | Trial closed | Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors | ahmad.awada@hubruxelles.be | 1/2 | 1 | |
22651 | Metastatic | Christiane Jungels | Multiple | Cantargia AB | CANFOUR | Trial closed | An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors | christiane.jungels@hubruxelles.be | 1/2 | 1 | |
22745 | metastatic, RECIST 1.1 | Alain Hendlisz | Colon | BMS - Bristol Myers Squibb int. | Checkmate 142 | Trial closed for recruitment | CA209-142 A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations, in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and non-MSI-H Colon Cancer. Checkmate 142 | alain.hendlisz@hubruxelles.be | 2 | 2 | |
22629 | all tumor types, any treatment line. | Alain Hendlisz | Multiple | Bordet | CHRONOS & KAIROS | Trial open for recruitment | CHRONOS & KAIROS Project : Creation of a Prospective Combined Clinical and Biological Database to Capture in Parallel the Patient?s Clinical History AND Tumoral Qualitative and Quantitative Changes During the Course of the Disease | alain.hendlisz@hubruxelles.be | 3 | 3 | |
22742 | colorectal cancer, metastatic or unresectable and for which standard treatments do not exist or are no longer effective. All standard chemotherapy agents (fluoropyrimidines, irinotecan and oxaliplatin) and monoclonal antibodies (bevacizumab, cetuximab an |
Alain Hendlisz | Colon | Institut Jules Bordet | CORIOLAN | Trial closed | CORIOLAN : Correlating the tumoral metabolic progression index measured by serial FDG PET-CT and apparent diffusion coefficient measured by MRI to patient's outcome in advanced colorectal cancer | alain.hendlisz@hubruxelles.be | |||
22681 | *NTSR1 expression *Measureable disease RECIST 1.1 |
Patrick Flamen | Germ cell tumors | Ipsen | D-FR-01087-001 | Trial closed | An international multi-center, open-label radioactivity escalation study to evaluate the safety, tolerability, biodistribution, and preliminary anti-tumor activity of 177Lu-3BP-227 for therapy in previously treated patients with advanced gastrointestinal cancers expressing neurotensin 1 receptors | patrick.flamen@hubruxelles.be | 1/2 | 1 | |
29368 | pancreas | Novartis | DaNIS-2 | Trial closed for recruitment | A randomized, double-blind, phase III study, comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) | 3 | 3 |